Peptide care · Pen
Elamipretide, also known as SS-31, has a narrowly defined FDA-approved use in Barth syndrome. That is separate from general healthy aging.
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Included because of mitochondrial biology. Clinical findings in Barth syndrome do not demonstrate greater energy or longer life in otherwise healthy adults.
Branded elamipretide received accelerated FDA approval for a defined Barth syndrome population. The initial randomized phase did not meet its primary endpoints; a longer uncontrolled extension informed the decision.
Read the publication
Mitochondrial biology explains the interest. The cited clinical work does not establish increased everyday energy or longer life in otherwise healthy adults.
Read the publicationSafety & suitability
The product label describes adverse reactions and monitoring. The approved indication and the limits of accelerated approval are central to interpreting this evidence.
FDA granted accelerated approval in 2025 to Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg. This is not an anti-aging approval or approval of a compounded SS-31 product.
FDA: Forzinity Drug Trials SnapshotSuitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
Clinical evidence concerns a specific medicine and a defined Barth syndrome population. It does not establish an everyday energy or anti-aging benefit from a compounded SS-31 preparation.
A small study in Barth syndrome · Subcutaneous branded elamipretide
The initial randomized phase did not meet its primary endpoints; the longer extension was uncontrolled. Confirmatory evidence is required.
Forzinity is a specific branded elamipretide medicine. Its evidence and approval do not establish equivalence or authorization of a compounded SS-31 preparation.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Three questions to help you discuss SS-31. Your clinician decides which preparation, checks and follow-up are relevant.
The preparation
What is the exact ingredient, formulation and strength, and how would it be used?
Your assessment
Which baseline measures would be relevant to my diagnosis and the exact preparation?
Your follow-up
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Medical Director & Physician, DarDoc
Physician, DarDoc
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
Forzinity is a specific branded elamipretide medicine. Its evidence and approval do not establish equivalence or authorization of a compounded SS-31 preparation.
The product label describes adverse reactions and monitoring. The approved indication and the limits of accelerated approval are central to interpreting this evidence.
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
Explore other compounds discussed in these health topics, with the evidence for each.
DarDoc peptidesHealthy aging · Sleep & focus
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
DarDoc peptidesRecovery · Healthy aging
A small human study found changes in growth-hormone secretion and selected strength measures, with no change in body composition.
DarDoc peptidesMetabolism · Healthy aging
A mitochondrial peptide studied in exercise biology. Animal treatment findings and measurements of naturally occurring MOTS-C in people are different kinds of evidence.
Bring your questions
Want to understand where SS-31 fits? Discuss the evidence, your health history and the options with DarDoc.
